Literature DB >> 8809445

IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications.

C Jorgensen1, M C Legouffe, C Bologna, J Brochier, J Sany.   

Abstract

OBJECTIVES: To study the clinical, biological and radiological characteristics of RA with a predominant increase of IgA isotype rheumatoid factor (IgA-RF) over IgM-RF.
METHODS: The presence of IgA-RF was determined by a sandwich-type ELISA with an antibody against the human IgA used to capture the immunoglobulin. Associated RF activity was revealed with a peroxidase-conjugated human IgG Fc fragment. Forty-nine RA patients were studied, of whom 19 had an increase in IgA-RF (38%). The control group comprised 30 RA patients without IgA-RF.
RESULTS: None of the patients had isolated IgA-RF. In the selected 19 RA patients, the OD of IgA-RF (0.971 +/- 0.62 U) was higher than the IgM-RF (mean OD: 0.675 +/- 0.522 U). A statistically significant correlation was found between IgA-RF and IgM-RF (r = 0.64, p < 0.0001). No correlation was noted between the IgA concentration and the IgA-RF titer. The two groups were comparable for age, disease duration, sex ratio and previous DMARD use. We observed that patients with RA associated with increased IgA-RF more often had the sicca syndrome, but no other extra-articular features. RA patients with IgA RF also had more erosive disease: the mean Larsen score at the hand and wrist was 76 (SD = 68) versus 54 (SD = 60) in the controls, p < 0.02. Replacement surgery for the hip or knee was necessary in 47% of the RA patients with IgA-RF, versus 13% in the controls, p < 0.01. No association of IgA-RF with disease activity was noted.
CONCLUSION: Our study showed that RA patients with a predominant increase of IgA-RF had a more erosive disease and a high frequency of associated sicca syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809445

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.

Authors:  H Chikazawa; K Nishiya; A Matsumori; K Hashimoto
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

2.  Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis.

Authors:  L Vasiliauskiene; A Wiik; M Høier-Madsen
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

3.  High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.

Authors:  Francesca Bobbio-Pallavicini; Roberto Caporali; Claudia Alpini; Stefano Avalle; Oscar M Epis; Catherine Klersy; Carlomaurizio Montecucco
Journal:  Ann Rheum Dis       Date:  2006-11-01       Impact factor: 19.103

4.  Anti-FcαRI Monoclonal Antibodies Resolve IgA Autoantibody-Mediated Disease.

Authors:  Amelie Bos; Esil Aleyd; Lydia P E van der Steen; P J Winter; Niels Heemskerk; Stephan M Pouw; Louis Boon; Rene J P Musters; Jantine E Bakema; Cassian Sitaru; Michel Cogné; Marjolein van Egmond
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

5.  Serum anti-malondialdehyde-acetaldehyde IgA antibody concentration improves prediction of coronary atherosclerosis beyond traditional risk factors in patients with rheumatoid arthritis.

Authors:  Hannah E Lomzenski; Geoffrey M Thiele; Michael J Duryee; Sheau-Chiann Chen; Fei Ye; Daniel R Anderson; Ted R Mikuls; Michelle J Ormseth
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

Review 6.  Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies.

Authors:  Y W Song; E H Kang
Journal:  QJM       Date:  2009-11-19

7.  Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA).

Authors:  Lillemor Berntson; Ellen Nordal; Anders Fasth; Kristiina Aalto; Troels Herlin; Susan Nielsen; Marite Rygg; Marek Zak; Johan Rönnelid
Journal:  Pediatr Rheumatol Online J       Date:  2014-06-11       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.